

SEB Fund 3 - SEB Medical Fund merges with SEB Concept Biotechnology

SEB Fund 3 - SEB Medical Fund merges with SEB Concept Biotechnology as of 21 April 2023.

Information for unitholders of SEB Concept Biotechnology (the receiving fund)

Information for unitholders of SEB Concept Biotechnology (the receiving fund)

We at SEB Investment Management AB work to continuously improve and refine our selection of funds. As part of this goal, the board of directors of the management company has decided that it is in the best interest of the unitholders to merge SEB Fund 3 - SEB Medical Fund, the merging sub-fund, with SEB Concept Biotechnology, the receiving fund. The merger will be effective as of 21 April 2023.

The merging sub-fund has experienced a continued weak investment interest in recent years and asset under management in the fund continues to be low. The merging sub-fund and the receiving fund have similar investment objectives and fundamental investment strategies and are managed by the same investment team. The management company believes that the merger will provide the benefit of a larger fund size which would result in greater efficiency from a portfolio management, operational, and cost-effective perspective.

How you as a unitholder are affected

The merger will not have any foreseeable impact on your investment in the receiving fund. SEB Concept Biotechnology continues to follow the same investment objective and strategy. The fund's fees remain the same.

This is a merger by absorption, whereby the merging sub-fund's holdings - assets and liabilities - will be transferred to the receiving fund, and SEB Fund 3 - SEB Medical Fund will cease to exist. The merger does not have a significant impact on the receiving fund's composition of assets, nor will it lead to any significant change having to be made before or after the merger. However, after the merger the portfolio manager will undertake rebalancing in the receiving fund which will incur transaction costs. Swing pricing will not be applied in this merger.

You are not required to act, but we think you as an investor should know about the merger. If you do not wish to remain invested in SEB Concept Biotechnology, you can redeem your units free of charge before the merger is finalized. Redemption can result in taxation. Kindly consult your financial advisor for more information.

SEB Investment Management AB bears any costs related to legal, advisory and administration actions arising from the merger.

Rights and trading information

If you wish to redeem your holdings in the receiving fund before the merger, the following applies:

21 April 2023: The merger is implemented.

As usual, we do not charge a fee for redemption or sale of fund units. The merger is not taxed in Luxembourg. However, redemption or switching may have tax implications for you, please contact your financial adviser for more information.

Unit classes and ISIN of the receiving fund

SEB Concept Biotechnology	
Unit class	ISIN code
D (USD)	LU2553409058
UD (USD)	LU2553409132

Legal names of the funds

Transferring sub-fund: SEB Fund 3 - SEB Medical Fund
Receiving Fund: SEB Concept Biotechnology

Additional information

The Luxembourg financial authority -CSSF has approved this merger.

The depositary statement and the approved statutory auditor report on the merger will be available, free of charge, on request from our registered office, SEB Investment Management AB, Luxembourg branch. Key Information Documents and prospectuses are available on www.sebgroup.lu/funds.

Sincerely,

SEB Investment Management AB, Luxembourg branch

March 2023

SEB Fund 3 - SEB Medical Fund merges with SEB Concept Biotechnology



**Past performance does not guarantee future performance. The value of investment funds and other financial instruments may rise as well as fall and there is no guarantee you will recover your original*

investment. The SEB Concept Biotechnology fund is classified as a higher risk fund and may, due to its composition and management methods, fall or rise sharply in value.